Good evening :)
Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd

FREDUN Share Price

NSE
₹1,572.005.63% (+83.80)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP

With a market cap of ₹2,515 cr, stock is ranked 1,156

Stock is 16.25x as volatile as Nifty

FREDUN Stock Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹2,515 cr, stock is ranked 1,156

Stock is 16.25x as volatile as Nifty

FREDUN Performance & Key Metrics

FREDUN Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
47.499.040.02%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
45.156.040.48%

FREDUN Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

FREDUN Company Profile

Fredun Pharmaceuticals Ltd manufactures pharmaceuticals formulations including dietary supplements, nutraceuticals, cosmeceuticals, animal healthcare products, and ortho rehabilitation aids marketed under multiple brands across generics, pet care, nutrition, skincare, and mobility segments.

FREDUN Similar Stocks (Peers)

Compare with peers Compare with peers 

FREDUN Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
35.90
35.90
1Y Return
6.26%
6.26%
Buy Reco %
93.55
93.55
PE Ratio
81.08
81.08
1Y Return
21.98%
21.98%
Buy Reco %
85.19
85.19
LAURUSLABS
PE Ratio
134.96
134.96
1Y Return
129.49%
129.49%
Buy Reco %
61.54
61.54
PE Ratio
21.66
21.66
1Y Return
28.80%
28.80%
Buy Reco %
57.69
57.69
PE Ratio
27.38
27.38
1Y Return
11.43%
11.43%
Buy Reco %
67.74
67.74
Compare with Peers

FREDUN Sentiment Analysis

FREDUN Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

FREDUN Stock Summary · June 2026

Management presented the quarter and year as a strong finish marked by robust revenue and margin expansion, underscored by FY26 total income of INR 639.12 crore and FY26 EBITDA of INR 94.79 crore. They conveyed a confident but conservative tone, reiterating a strategic pivot toward higher‑margin new‑age consumer lines — targeting a roughly 50/50 new‑age-to‑vintage mix near term and eventual 70/30 — while rolling out hormonal and anti‑aging portfolios, scaling a vertically integrated pet‑care platform, and accelerating a mobility division aimed at a INR 100 crore run‑rate within 2–2.5 years. Management attributed recent EBITDA expansion to faster new‑age growth and planned capacity additions to support diversification, but acknowledged tensions from elevated inventory (≈INR 270 crore against an ≈INR 700 crore topline) and the potential for working‑capital stretch during faster growth, noting debt‑to‑equity near 0.8 and positive operating cash flow. They described input‑cost pressures as managed through supplier ordering and buffers, and set FY27 revenue growth guidance of ~25%–30% with medium‑term PAT margins of roughly 10%–12%, saying current run‑rates are on track.

FREDUN Stock Growth Drivers
FREDUN Stock Growth Drivers
8
  • Sustained and materially improved financial performance

    The company reported strong near‑term and full‑year results, with Q4 total income of INR 213

  • Shift to higher‑margin 'new‑age' businesses driving margin expansion

    New‑age, consumer‑facing segments are expanding rapidly and contributing disproportionately to margins and growth; reported new‑age

FREDUN Stock Challenges
FREDUN Stock Challenges
4
  • Input cost inflation and near‑term margin pressure

    Geopolitical tensions have already driven raw material and input prices higher, creating upward pressure on

  • High working capital intensity and free cash flow disconnect

    The business exhibits persistently high working capital requirements tied to a large SKU base (about

FREDUN Forecast

FREDUN Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

FREDUN

FREDUN

Income

Balance Sheet

Cash Flow

FREDUN Income Statement

FREDUN Income Statement

Loading...

Quarterjun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026sep 2026
Total Revenue0.000.00288.86167.41119.86145.29160.92213.06228.25267.64
Operating & Other expensessubtract0.000.00251.20150.16102.86122.96134.59184.17195.51225.28
Depreciation/Amortizationsubtract0.000.003.201.841.421.891.783.153.573.93
Interest & Other Itemssubtract0.000.0014.238.156.537.7310.5514.498.628.78
Taxes & Other Itemssubtract0.000.006.491.262.273.273.520.477.4211.08
EPS0.000.009.704.244.786.667.406.577.9410.99

FREDUN Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual report

PDF
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF

Investor Presentation

Jun 15PDF
FY 2018FY 2018

Annual report

PDF
 

FREDUN Stock Peers

FREDUN Past Performance & Peer Comparison

FREDUN Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Fredun Pharmaceuticals Ltd77.109.040.02%
Sun Pharmaceutical Industries Limited35.905.340.86%
Torrent Pharmaceuticals Ltd81.0810.150.72%
Laurus Labs Ltd134.9622.080.09%
ScreenerCompare valuation on Screener

FREDUN Stock Price Comparison

Compare FREDUN with any stock or ETF
Compare FREDUN with any stock or ETF
FREDUN
Loading...

FREDUN Holdings

FREDUN Shareholdings

FREDUN Promoter Holdings Trend

FREDUN Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

FREDUN Institutional Holdings Trend

FREDUN Institutional Holdings Trend

Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 7.71%

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

FREDUN Shareholding Pattern

FREDUN Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding43.62%0.00%3.43%0.69%52.25%

Mar 2026

Jun 2026

Jul 2026

Sep 2026

FREDUN Shareholding History

FREDUN Shareholding History

Dec '25FebMarJunJulSep0.46%1.06%1.06%1.06%1.06%0.69%

Mutual Funds Invested in FREDUN

Mutual Funds Invested in FREDUN

No mutual funds holding trends are available

Top 1 Mutual Funds holding Fredun Pharmaceuticals Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.0005%0.06%0.06%98/146 (+34)

Compare 3-month MF holding change on Screener

FREDUN Insider Trades & Bulk Stock Deals

FREDUN Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing FREDUN stock

smallcases containing FREDUN stock

Looks like this stock is not in any smallcase yet.

FREDUN Events

FREDUN Events

FREDUN Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

FREDUN Dividend Trend

No dividend trend available

FREDUN Upcoming Dividends

FREDUN Upcoming Dividends

No upcoming dividends are available

FREDUN Past Dividends

FREDUN Past Dividends

Cash Dividend

Ex DateEx DateJun 23, 2026

Final
Final | Div/Share: ₹0.70

Dividend/Share

₹0.70

Ex DateEx Date

Jun 23, 2026

Cash Dividend

Ex DateEx DateSep 23, 2025

Final
Final | Div/Share: ₹0.70

Dividend/Share

₹0.70

Ex DateEx Date

Sep 23, 2025

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹0.70

Dividend/Share

₹0.70

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateSep 22, 2023

Final
Final | Div/Share: ₹0.70

Dividend/Share

₹0.70

Ex DateEx Date

Sep 22, 2023

Cash Dividend

Ex DateEx DateSep 16, 2021

Final
Final | Div/Share: ₹0.70

Dividend/Share

₹0.70

Ex DateEx Date

Sep 16, 2021

FREDUN Stock News & Opinions

FREDUN Stock News & Opinions

Corporate
Corporate
Fredun Pharmaceuticals' board reviewed a monitoring report for the quarter ended September 30, 2026

Fredun Pharmaceuticals Limited informed the BSE Limited that its Board of Directors met on Saturday, November 14, 2026, at 03:00 P.M. and noted the Monitoring Agency Report for the quarter ended September 30, 2026.

3 days agoCapital Market - Live
Corporate
Corporate
Fredun Pharmaceuticals confirms Rs 128.78 crore preferential issue use, despite reporting observations

Fredun Pharmaceuticals Limited reported no deviation or variation in the utilization of Rs 128.78 crore raised through a preferential issue during the quarter ended September 30, 2026, according to a regulatory filing. Care Ratings Limited, the monitoring agency, noted observations regarding the reporting and reconciliation of fund utilization, classification of balances, and verification of funds, but the company maintains that the proceeds have been utilized for the objects approved by shareholders, with differences arising from varying treatments of Cash Credit account balances and reporting methods.

3 days agoCapital Market - Live
Earnings
Earnings
Fredun Pharmaceuticals Ltd consolidated sales up 16.72% on year in Q3FY2026, net profit surged by 41.43%

Fredun Pharmaceuticals Ltd share price declined by 1.07% to Rs 1493.45. The Company's net profit saw a strong growth of 41.43% to Rs 18.57 crore, while revenue from operations gained 16.72% to Rs 265.85 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, gaining 5.09%. It has marginally improved by 2.18% over last one week and ticked higher by 2.72% in last one month while the market capitalization of Fredun Pharmaceuticals Ltd has improved by 9.33% and 24.30% in the same period respectively. Profit before tax (PBT) of Fredun Pharmaceuticals Ltd stood at Rs 29.65 crore in Q3 FY26, jumping 133.28% year-on-year, and expanding by 44.28% quarter-on-quarter. EBITDA came in at Rs 42 crore, surging by 89.70% YoY and rallying 29.38% sequentially. Total expenses advancing by 15.13% to Rs 229.21 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 241.21 crore, soaring by 34.21% YoY, while employee benefits expense was at Rs 9.11 crore, witnessing a strong rise of 27.95% YoY. For the TTM ended FY26, revenue from operations surged 40.21% to Rs 633.33 crore, while net profit jumped 65.25% to Rs 32.62 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 5712% to Rs 94.54 crore, and PBT witnessed a strong rise of 70.97% to Rs 47.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 115.25 crore in FY26, as against Rs 29.06 crore in FY25. Fredun Pharmaceuticals Ltd soared by 189.38% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 4.80% during the same period.

1 week agoCapital Market - Live
Earnings
Earnings
Fredun Pharmaceuticals Ltd consolidated sales up 16.72% on year in Q3FY2026, net profit soared by 41.43%

Fredun Pharmaceuticals Ltd share price gained 3.76% to Rs 1509.6 after the company's net profit jumped 41.43% to Rs 18.57 crore, while revenue from operations increased 16.72% to Rs 265.85 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, gaining 4.92%. It has marginally improved by 2.03% over last one week and crept higher by 1.77% in last one month while the market capitalization of Fredun Pharmaceuticals Ltd has improved by 4.07% and 25.64% in the same period respectively. Profit before tax (PBT) of Fredun Pharmaceuticals Ltd stood at Rs 29.65 crore in Q3 FY26, jumping 133.28% year-on-year, and rallying 44.28% quarter-on-quarter. EBITDA came in at Rs 42 crore, surging by 89.70% YoY and expanding by 29.38% sequentially. Total expenses rose by 15.13% to Rs 229.21 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 241.21 crore, soaring by 34.21% YoY, while employee benefits expense was at Rs 9.11 crore, surging 27.95% YoY. For the TTM ended FY26, revenue from operations jumped by 40.21% to Rs 633.33 crore, while net profit surged by 65.25% to Rs 32.62 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 5712% to Rs 94.54 crore, and PBT soared 70.97% to Rs 47.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 115.25 crore in FY26, as against Rs 29.06 crore in FY25. Fredun Pharmaceuticals Ltd rallied 192.88% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 7.38% during the same period.

1 week agoCapital Market - Live
Corporate
Corporate
Fredun Pharmaceuticals allots shares to warrant holders following board meeting on October 3, 2026

Fredun Pharmaceuticals Limited announced the allotment of 1,82,400 equity shares with a face value of Rs 10 each to warrant holders following the conversion of 60,800 warrants, as per a board meeting held on October 3, 2026. The allotment is linked to convertible warrants initially issued on December 29, 2025, and adjusted after the company’s 1:2 bonus issue, with a balance consideration paid by the warrant holders. The company also disclosed that ten investors received the allotted shares, with Rashmi Jain and Girdhari T Jaisinghani each receiving 4,000 shares.

1 month agoCapital Market - Live
Corporate
Corporate
Fredun Pharmaceuticals allotted shares to warrant holders following conversion and shareholder approval

Fredun Pharmaceuticals Limited announced the allotment of 1,82,400 equity shares with a face value of Rs 10 each to warrant holders following the conversion of 60,800 warrants, as approved by shareholders on October 22, 2025. The allotment, made on October 3, 2026, occurred after warrant holders paid the remaining consideration and exercised their conversion rights, with the entitlement adjusted after a 1:2 bonus issue, resulting in three equity shares for each outstanding warrant.

1 month agoCapital Market - Live
Corporate
Corporate
Fredun Pharmaceuticals allotted shares to warrant holders following conversion and shareholder approval

Fredun Pharmaceuticals Limited announced the allotment of 1,82,400 equity shares with a face value of Rs 10 each to warrant holders following the conversion of 60,800 warrants, as approved by shareholders on October 22, 2025. The allotment, made on October 3, 2026, occurred after warrant holders paid the remaining consideration and exercised their conversion rights, with the entitlement adjusted after a 1:2 bonus issue, resulting in three equity shares for each outstanding warrant.

1 month agoCapital Market - Live
Corporate
Corporate
Fredun Pharmaceuticals halts trading for insiders pending financial results announcement

Fredun Pharmaceuticals Limited will close its trading window for designated persons and their immediate relatives from Thursday, October 1, 2026, until 48 hours after the board meeting approves unaudited financial results for the quarter and half year ended September 30, 2026, according to a filing with the BSE Ltd.

1 month agoCapital Market - Live
Corporate
Corporate
Fredun Pharmaceuticals converts warrants, allotting shares to warrant holders and investors

Fredun Pharmaceuticals Limited has allotted 3,61,599 equity shares with a face value of Rs 10 each to warrant holders following the conversion of 1,20,533 warrants, as informed to the BSE Limited. The allotment is a result of warrant holders exercising their rights after paying the balance consideration, and it comes after a 1:2 bonus issue adjusted the warrants' entitlement. Alchemy Capital Management Pvt Ltd received the largest allotment of 24,000 shares, while a total of 10 non-promoter investors participated in the conversion.

1 month agoCapital Market - Live
Corporate
Corporate
Fredun Pharmaceuticals allots shares to warrant holders including Alchemy Capital and Ajay Aggarwal

Fredun Pharmaceuticals Limited announced the allotment of 2,71,200 equity shares with a face value of Rs 10 each to warrant holders, following the conversion of 90,400 warrants. The allotment, approved by shareholders on October 22, 2025, involved investors including Alchemy Capital Management Pvt Ltd, Alchemy Long Term Ventures Fund, Ajay Kumar Aggarwal, Divya Aggarwal, Swati Goel, Sweta Chokhany, Vartika Chokhany, Vivek Dhir, Ceramet Consultants Private Limited, and Nav Ratan Bhaiya. The conversion was adjusted following a 1:2 bonus issue made by the company, with each outstanding warrant now entitling the holder to three equity shares.

2 months agoCapital Market - Live

Frequently asked questions

  1. The share price of FREDUN as on 17th November 2026 is ₹1572. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Fredun Pharmaceuticals Ltd (FREDUN) share are
    • Past 1 week: 1.71%
    • Past 1 month: 6.53%
    • Past 3 months: 6.78%
    • Past 6 months: 105.08%
    • Past 1 year: 151.52%
    • Past 3 years: 445.83%
    • Past 5 years: 927.86%

  3. The current dividend yield of Fredun Pharmaceuticals Ltd (FREDUN) is 0.02.

  4. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Fredun Pharmaceuticals Ltd (FREDUN) is ₹2515.01 Cr as of 17th November 2026.

  5. The 52-week high of Fredun Pharmaceuticals Ltd (FREDUN) is ₹1665 and the 52-week low is ₹309.89.

  6. The P/E (price-to-earnings) ratio of Fredun Pharmaceuticals Ltd (FREDUN) is 77.10. The P/B (price-to-book) ratio is 9.04.

  7. Fredun Pharmaceuticals Ltd (FREDUN) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. You can directly buy Fredun Pharmaceuticals Ltd (FREDUN) shares on Tickertape. Simply sign up, connect your demat account and place your order.